Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 130

1.

Macrovascular effects and safety issues of therapies for type 2 diabetes.

Plutzky J.

Am J Cardiol. 2011 Aug 2;108(3 Suppl):25B-32B. doi: 10.1016/j.amjcard.2011.03.014. Review.

PMID:
21802578
2.

Oral antidiabetic agents: current role in type 2 diabetes mellitus.

Krentz AJ, Bailey CJ.

Drugs. 2005;65(3):385-411. Review.

PMID:
15669880
3.

Thiazolidinediones-benefits on microvascular complications of type 2 diabetes.

Viberti G.

J Diabetes Complications. 2005 May-Jun;19(3):168-77. Review.

PMID:
15866064
4.

Diabetes and peripheral vascular disease.

Huysman E, Mathieu C.

Acta Chir Belg. 2009 Oct;109(5):587-94. Review.

PMID:
19994800
5.

[Glycemic control and cardiovascular benefit: What do we know today?].

Hanefeld M, Schönauer M, Forst T.

Dtsch Med Wochenschr. 2010 Feb;135(7):301-7. doi: 10.1055/s-0029-1244853. Epub 2010 Feb 9. Review. German.

PMID:
20146161
6.

Glycemic control and complications in type 2 diabetes mellitus.

Stolar M.

Am J Med. 2010 Mar;123(3 Suppl):S3-11. doi: 10.1016/j.amjmed.2009.12.004. Review.

PMID:
20206730
7.

Impact of glycemic treatment choices on cardiovascular complications in type 2 diabetes.

Weiss IA, Valiquette G, Schwarcz MD.

Cardiol Rev. 2009 Jul-Aug;17(4):165-75. doi: 10.1097/CRD.0b013e3181a7b34c. Review.

PMID:
19525678
8.

Type 2 diabetes, cardiovascular risk, and the link to insulin resistance.

Stolar MW, Chilton RJ.

Clin Ther. 2003;25 Suppl B:B4-31. Review.

PMID:
14553864
9.

Hyperglycemia and microvascular and macrovascular disease in diabetes.

Klein R.

Diabetes Care. 1995 Feb;18(2):258-68. Review.

PMID:
7729308
10.

[Continuing care of patients with cardiovascular risk in general practice: diabetic patients and their care].

Ilyés I, Jancsó Z, Kovács E, Márton H, Simay A.

Orv Hetil. 2005 Dec 18;146(51):2581-8. Hungarian.

PMID:
16468612
11.

Evaluating cardiovascular safety of novel therapeutic agents for the treatment of type 2 diabetes mellitus.

Azim S, Baker WL, White WB.

Curr Cardiol Rep. 2014 Nov;16(11):541. doi: 10.1007/s11886-014-0541-0. Review.

PMID:
25303895
12.

Reducing cardiovascular complications of type 2 diabetes by targeting multiple risk factors.

Reasner CA.

J Cardiovasc Pharmacol. 2008 Aug;52(2):136-44. doi: 10.1097/FJC.0b013e31817ffe5a. Review.

PMID:
18670366
13.

Occurrence and interrelationships of complications in insulin-dependent diabetes in Finland.

Ebeling P, Koivisto VA.

Acta Diabetol. 1997 Mar;34(1):33-8.

PMID:
9134055
14.

A review of the response to oral antidiabetes agents in patients with type 2 diabetes.

Gavin JR 3rd, Bohannon NJ.

Postgrad Med. 2010 May;122(3):43-51. doi: 10.3810/pgm.2010.05.2141. Review.

PMID:
20463413
15.
16.

Therapeutic potential of aleglitazar, a new dual PPAR-α/γ agonist: implications for cardiovascular disease in patients with diabetes mellitus.

Cavender MA, Lincoff AM.

Am J Cardiovasc Drugs. 2010;10(4):209-16. doi: 10.2165/11539500-000000000-00000.

PMID:
20653327
17.

Glycemic control and macrovascular disease in types 1 and 2 diabetes mellitus: Meta-analysis of randomized trials.

Stettler C, Allemann S, Jüni P, Cull CA, Holman RR, Egger M, Krähenbühl S, Diem P.

Am Heart J. 2006 Jul;152(1):27-38. Review.

PMID:
16824829
19.

Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes.

ADVANCE Collaborative Group, Patel A, MacMahon S, Chalmers J, Neal B, Billot L, Woodward M, Marre M, Cooper M, Glasziou P, Grobbee D, Hamet P, Harrap S, Heller S, Liu L, Mancia G, Mogensen CE, Pan C, Poulter N, Rodgers A, Williams B, Bompoint S, de Galan BE, Joshi R, Travert F.

N Engl J Med. 2008 Jun 12;358(24):2560-72. doi: 10.1056/NEJMoa0802987. Epub 2008 Jun 6.

20.

[Treatment of diabetes in metabolic syndrome].

Pelikánova T.

Vnitr Lek. 2009 Jul-Aug;55(7-8):637-45. Review. Czech.

PMID:
19731868

Supplemental Content

Support Center